GT Biopharma (GTBP)

GT Biopharma (GTBP) Financial Statements


GT Biopharma Financial Overview

GT Biopharma's market cap is currently ―. The company's EPS TTM is $-0.285; its P/E ratio is -0.79; GT Biopharma is scheduled to report earnings on March 27, 2024, and the estimated EPS forecast is $-0.09. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue---$ 0.00$ 0.00
Gross Profit-----
EBIT$ -1.99M$ 39.00K$ -5.86M$ -6.88M$ -2.98M
EBITDA-$ 64.00K$ -5.84M$ -6.88M$ -2.98M
Net Income Common Stockholders$ -1.99M$ 251.00K$ -5.58M$ -6.88M$ -2.98M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 17.97M$ 19.95M$ 16.50M$ 20.78M$ 23.73M
Total Assets$ 18.14M$ 20.13M$ 16.74M$ 21.07M$ 24.17M
Total Debt$ 120.00K$ 147.00K$ 174.00K$ 198.00K$ 223.00K
Net Debt$ -17.85M$ -19.80M$ -16.33M$ -20.59M$ -23.50M
Total Liabilities$ 6.38M$ 7.03M$ 5.00M$ 5.12M$ 8.73M
Stockholders Equity$ 11.76M$ 13.05M$ 11.73M$ 15.95M$ 15.44M
Cash Flow-
Free Cash Flow-$ -2.90M$ -4.30M$ -2.92M$ -2.79M
Operating Cash Flow-$ -2.90M$ -4.30M$ -2.92M$ -2.79M
Investing Cash Flow-$ -6.99M$ 7.51M$ 25.00K$ 1.08M
Financing Cash Flow-$ 6.27M$ -1.00K$ 0.00$ -223.00K
Currency in USD

GT Biopharma Earnings and Revenue History

GT Biopharma Debt to Assets

GT Biopharma Cash Flow

GT Biopharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis